(CAH) Cardinal Health - Overview

Sector: Healthcare | Industry: Medical Distribution | Exchange: NYSE (USA) | Market Cap: 45.717m USD | Total Return: 30.2% in 12m

Pharmaceuticals, Medical Supplies, Surgical Equipment, Radiopharmaceuticals

Total Rating 63

Safety 57

Buy Signal 0.51

Medical Distribution
Industry Rotation: +2.7

Market Cap: 45.7B
Avg Turnover: 436M

Risk 3d forecast

Volatility24.3%

VaR 5^th Pctl4.02%

VaR vs Median0.29%

Reward TTM

Sharpe Ratio0.89

Rel. Str. IBD46.3

Rel. Str. Peer Group56

Character TTM

Beta0.186

Beta Downside-0.100

Hurst Exponent0.595

Drawdowns 3y

Max DD20.42%

CAGR/Max DD1.74

CAGR/Mean DD7.22

EPS (Earnings per Share)

EPS CAGR: 18.69%
EPS Trend: 96.4%

Last SUE: 3.10
Qual. Beats: 3

Revenue

Rev. CAGR: 5.93%
Rev. Trend: 90.7%

Last SUE: -0.73
Qual. Beats: 0

Warnings

Altman Z'' -0.18 < 1.0 - financial distress zone

Tailwinds

Confidence, Garp

Description: CAH Cardinal Health

Cardinal Health, Inc. (CAH) is a global healthcare services provider operating through two primary segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company functions as a critical intermediary in the healthcare supply chain, distributing branded and generic pharmaceuticals, over-the-counter products, and medical-surgical supplies to hospitals, pharmacies, and clinical laboratories.

The business model relies on high-volume, low-margin distribution, where profitability is driven by scale and supply chain efficiency. As a member of the Big Three pharmaceutical distributors in the United States, Cardinal Health benefits from an oligopolistic market structure that services the vast majority of domestic prescription drug volume.

In addition to distribution, the company manufactures its own branded medical products, including surgical apparel, wound care, and fluid management systems. It also operates specialized business units for radiopharmaceuticals and pharmacy management services. For a deeper look into the companys valuation metrics, consider reviewing the data on ValueRay.

Headquartered in Dublin, Ohio, Cardinal Health supports integrated healthcare delivery by providing logistics, technology solutions, and sterile procedure kit assembly. The company’s infrastructure is essential for the daily operations of ambulatory surgery centers and physician offices worldwide.

Headlines to Watch Out For

Pharmaceutical distribution volume and drug pricing trends drive consistent segment revenue growth
Expansion of high-margin specialty medicine services improves consolidated operating profit margins
Generic drug price deflation and brand-to-generic conversion cycles impact distribution profitability
Medical segment restructuring and supply chain efficiency initiatives influence long-term earnings potential

Piotroski VR‑10 (Strict) 6.5

Net Income: 1.56b TTM > 0 and > 6% of Revenue
FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.86 > 1.0
NWC/Revenue: -1.57% < 20% (prev -0.93%; Δ -0.64% < -1%)
CFO/TA 0.09 > 3% & CFO 5.01b > Net Income 1.56b
Net Debt (4.98b) to EBITDA (3.04b): 1.64 < 3
Current Ratio: 0.91 > 1.5 & < 3
Outstanding Shares: last quarter (236.0m) vs 12m ago -2.07% < -2%
Gross Margin: 3.68% > 18% (prev 0.04%; Δ 364.9% > 0.5%)
Asset Turnover: 470.2% > 50% (prev 445.4%; Δ 24.85% > 0%)
Interest Coverage Ratio: 6.38 > 6 (EBITDA TTM 3.04b / Interest Expense TTM 343.0m)

Altman Z'' -0.18

A: -0.07 (Total Current Assets 38.06b - Total Current Liabilities 41.99b) / Total Assets 56.69b
B: 0.03 (Retained Earnings 1.73b / Total Assets 56.69b)
C: 0.04 (EBIT TTM 2.19b / Avg Total Assets 53.28b)
D: -0.10 (Book Value of Equity -5.65b / Total Liabilities 59.36b)
Altman-Z'' Score: -0.18 = B

Beneish M -3.02

DSRI: 0.96 (Receivables 13.65b/12.67b, Revenue 250.55b/222.13b)
GMI: 0.96 (GM 3.68% / 3.52%)
AQI: 1.09 (AQ_t 0.28 / AQ_t-1 0.25)
SGI: 1.13 (Revenue 250.55b / 222.13b)
TATA: -0.06 (NI 1.56b - CFO 5.01b) / TA 56.69b)
Beneish M-Score: -3.02 (Cap -4..+1) = AA

What is the price of CAH shares? As of May 21, 2026, the stock is trading at USD 199.23 with a total of 1,485,131 shares traded.
Over the past week, the price has changed by +6.91%, over one month by -5.66%, over three months by -11.02% and over the past year by +30.18%.

Is CAH a buy, sell or hold? Cardinal Health has received a consensus analysts rating of 4.12. Therefore, it is recommended to buy CAH.

StrongBuy: 9
Buy: 2
Hold: 5
Sell: 1
StrongSell: 0

What are the forecasts/targets for the CAH price?

Analysts Target Price	245.3	23.1%

Cardinal Health (CAH) - Fundamental Data Overview as of 18 May 2026

P/E Trailing = 29.7561
P/E Forward = 15.456
P/S = 0.1823
P/B = 16.0657
P/EG = 1.1372
Revenue TTM = 250.55b USD
EBIT TTM = 2.19b USD
EBITDA TTM = 3.04b USD
Long Term Debt = 8.24b USD (from longTermDebt, last quarter)
Short Term Debt = 671.0m USD (from shortTermDebt, last quarter)
Debt = 8.92b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.98b USD (from netDebt column, last quarter)
Enterprise Value = 50.70b USD (45.72b + Debt 8.92b - CCE 3.94b)
Interest Coverage Ratio = 6.38 (Ebit TTM 2.19b / Interest Expense TTM 343.0m)
EV/FCF = 11.54x (Enterprise Value 50.70b / FCF TTM 4.39b)
FCF Yield = 8.66% (FCF TTM 4.39b / Enterprise Value 50.70b)
FCF Margin = 1.75% (FCF TTM 4.39b / Revenue TTM 250.55b)
Net Margin = 0.62% (Net Income TTM 1.56b / Revenue TTM 250.55b)
Gross Margin = 3.68% ((Revenue TTM 250.55b - Cost of Revenue TTM 241.32b) / Revenue TTM)
Gross Margin QoQ = 4.10% (prev 3.38%)
Tobins Q-Ratio = 0.89 (Enterprise Value 50.70b / Total Assets 56.69b)
Interest Expense / Debt = 1.13% (Interest Expense 101.0m / Debt 8.92b)
Taxrate = 3.06% (12.0m / 392.0m)
NOPAT = 2.12b (EBIT 2.19b * (1 - 3.06%))
Current Ratio = 0.91 (Total Current Assets 38.06b / Total Current Liabilities 41.99b)
Debt / Equity = -3.15 (negative equity) (Debt 8.92b / totalStockholderEquity, last quarter -2.83b)
Debt / EBITDA = 1.64 (Net Debt 4.98b / EBITDA 3.04b)
Debt / FCF = 1.13 (Net Debt 4.98b / FCF TTM 4.39b)
Total Stockholder Equity = -2.80b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.93% (Net Income 1.56b / Total Assets 56.69b)
RoE = -55.72% (negative equity) (Net Income TTM 1.56b / Total Stockholder Equity -2.80b)
RoCE = 40.15% (EBIT 2.19b / Capital Employed (Equity -2.80b + L.T.Debt 8.24b))
RoIC = 35.15% (NOPAT 2.12b / Invested Capital 6.03b)
WACC = 5.74% (E(45.72b)/V(54.63b) * Re(6.64%) + D(8.92b)/V(54.63b) * Rd(1.13%) * (1-Tc(0.03)))
Discount Rate = 6.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -96.61 | Cagr: -1.83%
[DCF] Terminal Value 84.94% ; FCFF base≈3.61b ; Y1≈3.17b ; Y5≈2.60b
[DCF] Fair Price = 313.9 (EV 78.51b - Net Debt 4.98b = Equity 73.53b / Shares 234.2m; r=6.0% [WACC]; 5y FCF grow -14.88% → 3.0% )
EPS Correlation: 96.42 | EPS CAGR: 18.69% | SUE: 3.10 | # QB: 3
Revenue Correlation: 90.74 | Revenue CAGR: 5.93% | SUE: -0.73 | # QB: 0
EPS next Quarter (2026-09-30): EPS=2.87 | Chg30d=+2.19% | Revisions=+60% | Analysts=8
EPS current Year (2026-06-30): EPS=10.77 | Chg30d=+4.50% | Revisions=+79% | GrowthEPS=+30.7% | GrowthRev=+15.0%
EPS next Year (2027-06-30): EPS=11.98 | Chg30d=+3.45% | Revisions=+79% | GrowthEPS=+11.2% | GrowthRev=+8.3%
[Analyst] Revisions Ratio: +79%